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Abstract
Background: Physical activity (PA) is frequently restricted in people with multiple sclerosis (PwMS) and aiming
to enhance PA is considered beneficial in this population. We here aimed to explore two standard methods
(subjective plus objective) to assess PA reduction in PwMS and to describe the relation of PA to health-related
quality of life (hrQoL).
Methods: PA was objectively measured over a 7-day period in 26 PwMS (EDSS 1.5–6.0) and 30 matched healthy controls
(HC) using SenseWear mini® armband (SWAmini) and reported as step count, mean total and activity related
energy expenditure (EE) as well as time spent in PA of different intensities. Measures of EE were also derived
from self-assessment with IPAQ (International Physical Activity Questionnaire) long version, which additionally
yielded information on the context of PA and a classification into subjects’ PA levels. To explore the convergence between
both types of assessment, IPAQ categories (low, moderate, high) were related to selected PA parameters from objective
assessment using ANOVA. Group differences and associated effect sizes for all PA parameters as well as their relation to
clinical and hrQoL measures were determined.
Results: Both, SWAmini and IPAQ assessment, captured differences in PA between PwMS and HC. IPAQ categories fit well
with common cut-offs for step count (p = 0.002) and mean METs (p = 0.004) to determine PA levels with objective
devices. Correlations between specifically matched pairs of IPAQ and SWAmini parameters ranged between r .288
and r .507. Concerning hrQoL, the lower limb mobility subscore was related to four PA measures, while a relation
with patients’ report of general contentment was only seen for one.
Conclusions: Both methods of assessment seem applicable in PwMS and able to describe reductions in daily PA
at group level. Whether they can be used to track individual effects of interventions to enhance PA levels needs
further exploration. The relation of PA measures with hrQoL seen with lower limb mobility suggests lower limb
function not only as a major target for intervention to increase PA but also as a possible surrogate for PA changes.
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Background
A low level of physical activity (PA) is a known risk fac-
tor for health outcomes and effects on disease outcomes
have been described in several conditions [1–3].
Also in people with multiple sclerosis (PwMS), aiming
to enhance PA is considered beneficial [4]. Like in other
chronic disorders, PA assessment may serve as a marker
of disability status [5] with different aims: on the one
hand to select individuals that may benefit from inter-
vention and to track effects of behavioral interventions
and on the other hand to investigate how and which
functional changes translate into real-life activity [6].
We here use the term PA according to the classic
definition as “all muscle activity exerted by an individual
resulting in energy expenditure (EE) above resting EE”
[7]. Thus, the intensity of PA is usually expressed in
multitudes of individual resting EE, designated as meta-
bolic equivalent of task (MET, unit of work/ kg body
weight/ hour), with estimates assigned to different types of
PA [8–10]. According to their assigned MET, PA is usually
categorized as low, moderate or vigorous activity (LPA,
MPA, VPA). In contrast, daily step count or time spent
walking specifically refer to locomotor activity which can
take on different intensities, e.g. depending on walking
speed or inclination. General levels of PA are most often
described as step count, total daily EE, activity related EE
or time of the day spent active/ inactive as defined by
MET thresholds.
The different methods used to assess PA capture different
aspects and have their specific limitations [10–13]. The
International Physical Activity Questionnaire (IPAQ) [14] is
a standardized self-rating questionnaire based on recall over
the previous week.
Several portable activity monitors have become available
for objective PA assessment [3, 10, 12, 15–17]. Accuracy
of the multi-sensor device SenseWear Pro was acceptable
in PwMS [18] against indirect calorimetry as standard,
while - to our knowledge - the successor SWAmini with
reportedly improved performance [19–21] has not been
applied in PwMS. We therefore aim to explore its applic-
ability in this population and convergence of results with
those obtained from subjective assessment (IPAQ long
version). From previous reports we expect lower levels of
daily PA to be associated with more severe symptoms of
MS and reduced health-related quality of life (hrQoL). By
correlation of PA measures with an MS-specific quality of
life questionnaire, we aim to define which aspects of MS-
related functional impairment relate most closely to
decline in daily PA level in PwMS.
Methods
Study participants
Study participants were enrolled at a university MS refer-
ral center. Inclusion criteria for all participants were: age
18–65 years, no cardiovascular disease, orthopedic or
other conditions thought to affect motor performance or
daily activity and additionally for healthy controls (HC)
without neurological diagnosis: no impairment of gait or
balance evident at testing. Further inclusion criteria for
PwMS were: MS diagnosis according to McDonald Cri-
teria 2010 [22], EDSS between 0 and 6, no relapses for at
least 30 days prior to study visit, no other neurologic
comorbidity. The study was approved by the local ethics
committee of the Charité - Universitätsmedizin Berlin
(EA1/321/14) and conducted in conformity with the Dec-
laration of Helsinki in its currently applicable form. All
participants gave written informed consent.
Objective assessment of daily PA with SWAmini
We used the physical activity monitor SenseWear® Arm-
band and Software Development Kit Version 8.1.1.30 (Sen-
seWear Model Mini, MF-SW; BodyMedia®, Inc. Pittsburgh,
Pennsylvania, USA). Subjects were instructed to wear the
SWAmini over 7 days (including the weekend) throughout
the day and to take the sensor off during night rest and for
any water activity. The monitor was placed at the middle of
the triceps brachii muscle (left arm) according to the user
manual [23]. The device reports individual wearing times
that served to prove subjects’ compliance.
SWAmini reports physical activity as accelerometrically
derived step count and as estimates of individual EE from
1-min epochs of recording based on algorithmic integration
of multi-sensor data incorporating subject’s age, sex and
body size. EE is reported as total MET per recording time
(mean METs) and activity related EE (active METs). One
MET represents estimated resting EE and by convention
equals 1 kcal/ kg body weight/h. The intensity of PA within
each epoch is classified according to MET cut-offs of 1.5–3
for light PA (LPA), MET 3 – 6 for moderate PA (MPA),
MET 6–9 for vigorous PA (VPA) and MET> 9 for very vig-
orous PA (VVPA). Duration of PA per intensity is reported
in min/hour, calculated as SWAmini output per day divided
by individual daily wearing time, MPA and VPA values
were combined into MVPA for some analyses. A list of
parameters is available as Additional file 1: Table S1.
To account for possible difference in PA behavior
between weekdays and weekend, a weighted mean was
calculated as follows:
parameter mean weekend 2ð Þ þ parameter mean weekday  5ð Þ
7
For comparison with IPAQ data, activity-related EE
was given in MET*min/day calculated as SWAmini
mean active METs times duration of all MET > 3 activity
per day. Similarly, SWAmini MPA and VPA duration in
min/hour were transformed into min/day by multiplica-
tion with the mean daily hours of wearing time.
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Subjective assessment of daily PA with IPAQ long version
We used the German (Austrian) translation of the IPAQ
long version [14] that reports the amount and intensity of
patients’ PA by recall of the past 7 days. The questionnaire
was applied in paper-pencil form after the week of SWA-
mini recording and thus, IPAQ data refer to the same time
span as SWAmini recordings.
After application of data cleaning rules according to the
scoring manual [24] IPAQ results were coded, first, as
time per day spent in PA of different intensity, i.e. time
spent walking (IPAQ Walking duration), time spent in
moderate (IPAQ MPA duration) or vigorous PA (IPAQ
VPA duration), that can be summed to total duration of
daily PA (IPAQ Total duration). Data are usually pre-
sented as min/week that we transformed into min/day for
comparison with SWAmini data. As the MET-value of 3.3
assigned for walking in the IPAQ [14] is above the MET-
threshold for MPA in the SWAmini, we computed a
combined parameter from IPAQ Walking duration +
IPAQ MPA duration for comparison. Second, results were
rendered as estimates of active EE by multiplication of
duration of activity with predefined MET values given in
MET*min/week that we transformed into MET*min/day
for comparison with SWAmini. Third, both the duration
and intensity of PA were coded separately in four ADL
domains: work, active transportation, domestic/yard and
leisure/sports that were reported as EE per domain in %
of total active EE. Fourth, we applied the scoring rules to
classify individuals into the IPAQ categories of low,
moderate and high PA level.
In sum, IPAQ long form yielded three main outcomes: 1)
the activity related EE as well as time spent for walking,
MPA and VPA, 2) the distribution of EE in the four differ-
ent ADL domains and 3) a three-step classification of PA
level. In addition, we derived information on occupational
status out of IPAQ results.
Clinical severity and health-related Quality of Life
In PwMS, a neurological examination with the Expanded
Disability Status Scale (EDSS) scoring [25] was performed
prior to SWAmini assessment. The Hamburg Quality of
Life Questionnaire in Multiple Sclerosis (HAQUAMS ver-
sion 10.0) was applied in paper form in its German version
(HALEMS) [26, 27]. It consists of 44 items, 28 of which
contribute to the total score between 1 (unimpaired) and
5 (very much impaired) as the mean of the following six
subscores: fatigue, thinking, mobility lower limb, mobility
upper limb, communication and mood. We added a
sensory (items 4 and 5) and bladder/bowel (items 26–28)
subscore, as we assumed these may impact on subjects’
daily PA. As a general measure of overall contentment in
life – irrespective of any disease specific impairment – we
included item 43 (score 1–5) into analysis.
Statistical analysis
Differences between groups (HC and PwMS) regarding
sex and occupational status were calculated using the χ2-
test while independent sample t-tests were applied with
regard to age, height, weight and BMI and SWAmini
parameters. Differences of SWAmini parameter means
between weekdays and weekends were explored by paired
t-test, separately for each group. Group differences for
SWAmini parameters were also expressed as effect sizes
(Cohen’s d) calculated as mean between-group difference
divided by the standard deviation in HC. Between-group
differences regarding IPAQ parameters of duration and
EE were explored using Mann–Whitney-U-tests. The pro-
portions of IPAQ Total EE spent in the four domains
work, transportation, domestic and leisure as well as the
distribution of subjects into IPAQ categories of low,
moderate and high PA level was compared between
groups with χ2-test.
We used Spearman rank correlation for IPAQ data,
EDSS and HAQUAMS total and subscores. To relate
SWAmini parameters step count and mean METs to the
IPAQ categories of low, moderate and high PA level, we
applied ANOVA with Bonferroni post-hoc testing, while
EDSS scores were related to the IPAQ categories with
Jonckheere-Terpstra-Test.
All analyses relating SWAmini to IPAQ as well as
inter-correlations of SWAmini parameters (presented as
Additional files 1, 2, 3 and 4) were performed for the whole
group, while correlations with EDSS and HAQUAMS were
only analyzed in PwMS.
Statistical analysis was performed with SPSS version
22 (IBM, Armonk, NY, USA). All tests were two-tailed,
significance was assumed when p < 0.05. No alpha-error
correction for multiple testing was applied in this
exploratory study.
Results
Study cohort and data cleaning
From November 2014 to August 2015, 29 PwMS and 30
gender- and age-matched HC were included into the
study. Three PwMS were excluded because of incorrect
use of the SWAmini (2) or missing SWAmini-data (1).
IPAQ data were missing in one HC, and data of one
PwMS were excluded in the data cleaning process
(>960 min of daily activity time). Truncation of IPAQ
active time according to the IPAQ manual had to be
applied in 5 subjects (3 HC and 2 PwMS). Data in
HAQUAMS item 43 (contentment) were missing in one
PwMS. Thus, analyses refer to 26 PwMS and 30 HC
(Table 1), while analyses comprising IPAQ data refer to
26 PwMS and 29 HC. A higher rate of unemployment
was noted among PwMS that seemed related to higher
EDSS (Table 1, Additional file 3: Figure S1).
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SWAmini: objectively assessed daily PA
Only small differences between parameter means from
weekend and weekday were seen in HC with 0.15 lower
active METs (p = 0.049) on weekends. No difference was
seen for any parameter in PwMS between weekend/
weekday. Therefore, all further SWAmini analyses refer
to a weighted mean.
Between-group differences - that is, HC performing
better than PwMS - were observed in all parameters
except light PA (p < 0.01, Table 2). Highest effect sizes
(Cohen’s d ≥ 0.85) were seen with step count, mean and
active METs, while other parameters yielded effect sizes
between 0.63 and 0.75 (Table 2).
As expected from the observed between-group
differences, the correlations of SWAmini parameters
with EDSS were not significant for time spent in light
activities, but pointed to a decrease of higher intensity
PA with higher EDSS (Fig. 1), reflected in decreased
step count (r −0.534, p = 0.005), mean METs (r −0.411,
p = 0.037), MPA and MVPA (r −0.477, p = 0.014 and r
−0.451, p = 0.021). The lack of correlation with VPA
and active METs (r −0.327, p = 0.103 and r −0.175, p =
0.394) is likely due to the generally low amount of
VPA in this group with no VPA recorded in 6 of 26
PwMS (Table 2).
IPAQ: subjectively assessed daily PA
Concerning the proportional distribution of IPAQ total
EE into ADL domains, a trend for group differences was
noted (p = 0.089, Table 2) with a tendency of PwMS to
spend a smaller part of their daily total EE in active
transportation/work but a larger part in leisure and
domestic activities (Table 2). This suggests active trans-
portation as a work-related activity.
Second, we explored group differences in total durations
of PA irrespective of their contextual domain (Walking,
MPA, VPA, MVPA and Total PA duration). PwMS
reported less time spent in moderate PA (MWU; MPA p
= 0.010 and MVPA p = 0.016), while no significant differ-
ences were seen for walking, vigorous PA, total PA
duration as well as total activity-related EE (Table 2). It
should be noted for interpretation that as with SWAmini,
a considerable number of subjects reported no vigorous
(14 HC and 17 PwMS) or even moderate activities (6 HC
and 14 PwMS). Similar to SWAmini, reduced PA in
PwMS was associated with higher EDSS scores (Fig. 2) for
IPAQ Total duration (r −0.752, p < 0.001), IPAQ Total EE
(r −0.572, p = 0.003), IPAQ Walking duration (r −0.462; p
= 0.020,) MPA duration (r −0.469, p = 0.018), VPA
duration and MVPA duration (r −0.428, p = 0.033 and r
−0.424, p = 0.035).
Third, we compared the distribution of subjects into
the three IPAQ categories of low – moderate – high PA
level between groups (Fig. 3a). There was a tendency of
HC to be more frequently classified as moderate or high
PA level and less frequently as low PA level compared to
PwMS (X2 test, p = 0.150, Fig. 3a). EDSS scores differed
across the IPAQ PA levels with higher EDSS scores in
PwMS assigned as low activity level and low EDSS of 3
in the one highly active MS subject (Jonckheere-Terpstra
test; p = 0.027; Fig. 3b).
SWAmini and IPAQ: associations between subjectively
and objectively assessed daily PA
For testing convergence of both methods we correlated
three matching pairs of PA parameters (Additional file 4:
Figure S2). The combined parameter moderate PA and
walking duration from the IPAQ showed a remarkable
association with moderate PA assessed with SWAmini
(IPAQ MPA +Walking duration and SWAmini MPA
Spearman r .507, p < 0.001); subjectively assessed total
EE was associated with respective active EE assessed
with SWAmini (IPAQ Total EE and SWAmini active EE
r .336, p = 0.013) and subjective duration of vigorous
Table 1 Cohort overview – demographic and clinical data per subject group
HC PwMS p-value
Subjects N 30 26
Relapsing MS 18
Progressive MS 8 (7 SPMS; 1 PPMS)
Sex Male /female 10 /20 10 /16 .783
Occupational status without employment/ working 6/23 14/12 .013*
Age (years) Mean (±SD) 49.7 (±8.3) 50.9 (±5.2) .522
BMI Mean (±SD) 25.3 (±3.9) 26.0 (±3.5) .474
Height (m) Mean (±SD) 1.70 (±7.4) 1.71 (±6.6) .398
Weight (kg) Mean (±SD) 73.8 (±13.7) 76.8 (±12.9) .588
EDSS Median (Min-Max) . 4.0 (1.5–6.0)
Independent sample t-test was used for between-group comparison of age, BMI, weight and height and χ2-test was used to compare sex and occupational status.
Please note that IPAQ-data and thus occupational status from 1 HC is missing. *denotes significance at level <0.05
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activities duration was related to the corresponding ob-
jectively assessed parameter (IPAQ VPA duration and
SWAmini VPA duration r .288, p = 0.035). Interestingly,
of the nine subjects with objectively no vigorous activ-
ities (3 HC, 6 PwMS), eight (3 HC, 5 PwMS) reported
also no vigorous activities with IPAQ, while vice versa,
in subjects with no self-perceived vigorous PA between
0–28 min/day were recorded with SWAmini.
In the second approach, we related the three IPAQ
categories of PA level to those SWAmini parameters that
have been proposed as classification criteria for indi-
vidual activity level: total daily step count and mean
METs. As expected, both parameters increased from
low to moderate to high IPAQ activity level (ANOVA
p = 0.002 for step count per day, p = 0.004 for mean
METs per day, Fig. 3c and d). Post-hoc analyses
Table 2 Amount and intensity of daily physical activity in HC and PwMS assessed with wearable device (SWAmini) reported as
weighted mean (± SD) and subjective assessment with IPAQ long version reported as median (interquartile range) from a 7-day
period
Healthy controls PwMS p-value Cohen’s d
N = 30 N = 26
Objective
(SWAmini)
Step count (steps/hour) 563.45 (±155.90) 430.66 (±171.68) .004 0.85
Mean METs (mean/day) 1.77 (±.28) 1.53 (±.16) <.001 0.86
Active METs (mean/day) 4.41 (±.59) 3.90 (±.46) .001 0.86
Total EE (kcal/hour) 387.40 (±237.40) 214.08 (±194.20) .004 0.73
Active EE (kcal/hour) 118.13 (±110.65) 37.89 (±41.73) .001 0.75
Active EE (MET*min/day) 410.79 (±257.07) 217.70 (±116.19) .001 0.75
LPA (min/hour) 2.98 (±2.47) 3.90 (±3.27) .249 0.37
MPA (min/hour) 5.38 (±2.63) 3.73 (±1.80) .008 0.63
MVPA (min/hour) 6.23 (±3.21) 3.91 (±1.93) .002 0.72
VPA (min/hour) .844 (±.927) *3 .176 (±.403) *6 .001 0.72
VVPA (min/hour) .148 (±.426) *21 .001 (±.002) *25 .084 0.35
Full days worn (days/period) 7.23 (±1.36) 7.81 (±1.77) .220 -
Mean daily wearing time (hours/day) 15.38 (±1.73) 14.29 (±1.58) .017 -
Self-perceived
(IPAQ)
Walking duration (min/day) 27.86 (45.71) *2 34.29 (71.14) *2 .664
MPA duration (min/day) 51.43 (91.79) *6 0.00 (53.57) *14 .010
MVPA duration (min/day) 68.19 (101.79) *6 0.00 (60.00) *13 .016
VPA duration (min/day) 2.86 (25.71) *14 0.00 (17.14) *17 .259
Total duration (min/day) 108.57 (120.36) 81.43 (135.00) .327
Total EE (MET*min/day) 516.57 (502.04) 501.14 (596.44) .440
Work EE (mean % of total EE and
interquartile range)
19.12% (31.22) *8,
6 unemployed
12.66% (17.34) *5,
14 unemployed
.089
Transportation EE (mean % of total
EE and interquartile range)
34.41% (43.38) *2 28.42% (40.53) *2
Domestic EE (mean % of total EE
and interquartile range)
24.93% (22.43) *2 28.34% (33.76) *3
Leisure EE (mean % of total EE
and interquartile range)
21.54% (28.70) *4 30.58% (36.59) *2
IPAQ category (n and % of group): .150
Low 5 (17.2%) 10 (40.0%)
Moderate 21 (72.4%) 14 (56.0%)
High 3 (10.3%) 1 (4.0%)
Subjects were instructed to wear SWAmini during the waking day excluding water activities. P-values for between-group differences of SWAmini parameters refer
to t-tests. IPAQ-data (comprising 29 HC and 25 PwMS) were compared between groups using Mann–Whitney-U-test, except for χ2-test used to compare the distribution
of subjects into different IPAQ physical activity levels and the percentages of total EE spent in different activity domains. Please note that percentage values in IPAQ
work EE were set to a value of 0 for unemployed subjects. Numbers of subjects per group that were not assigned any activity for MPA/VPA/VVPA are given with asterisk;
these individuals were assigned a value of 0 for the calculation of means
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indicated a better differentiation between high and mod-
erate PA level by step count and between moderate and
low PA level by mean METs (Fig. 3c and d).
HAQUAMS: the impact of MS on quality of life related to
daily PA
The distribution of HAQUAMS total and subscores were
found as expected from other MS cohorts of similar dis-
ease stage without major floor or ceiling effects (Tables 3
and 4). HAQUAMS total had a median of 2.20 (range
from 1.20 to 3.39) and the median of the single item 43
(global contentment) was 2.00 (range from 1 to 4) with
only two subjects scoring category 1 or 4, respectively.
Lower EDSS scores were strongly associated with better
self-perceived hrQoL in the subscores mobility lower limb
(r 0.590, p = 0.002), mobility upper limb (r 0.479, p =
0.013) and global contentment (r 0.445, p = 0.026), but not
with other subscores or HAQUAMS total.
When we explored the relation of HAQUAMS total and
subscores with the amount of daily PA from both, objective
and subjective assessment, correlations of moderate magni-
tude were seen with HAQUAMS subscore mobility lower
limb for four PA parameters: step count, moderate PA
assessed objectively and subjectively as well as subjective
vigorous PA (Tables 3 and 4), all pointing to higher PA
levels being associated with better self-perceived lower limb
function. In addition, vigorous PA assessed with SWAmini
showed moderate correlation to HAQUAMS pain/sensory
subscore (Tables 3 and 4). In contrast, PA parameters were
not related to HAQUAMS total or global contentment,
except for its moderate correlation with IPAQ Total EE.
This argues against a genuine impact of perceived hrQoL
on daily PA or vice versa, although correlation analyses are
surely limited by small sample size. Considering this, trends
seen for the correlation of HAQUAMS contentment with
IPAQ Total duration, SWAmini active METs and vigorous
PA as well as HAQUAMS total with SWAmini moderate
PA and of HAQUAMS fatigue subscore with IPAQ
moderate/vigorous PA and SWAmini mean METs and
light PA deserve further investigation.
Discussion
The amount of daily physical activity was reduced in PwMS
compared to HC. This was expected from previous reports
[28–30] as well as from the theoretical conceptualization of
PA as the behavioral correlate of disability in MS [31, 32].
Given that the vast majority of evidence on PA in PwMS is
Fig. 1 Selected activity parameters from SWAmini related to EDSS score.
a Steps per day, b Mean METs and c MVPA. Results of HCs are depicted
in yellow for reference, all PwMS results are depicted in dark blue. Lines
refer to median, boxes to interquartile range and whiskers to maximum
and minimum excluding outliers (outlier defined as > 1.5 IQR of upper or
lower quartile)
Krüger et al. BMC Neurology  (2017) 17:10 Page 6 of 12
from US cohorts, this is also the first confirmatory study in
German MS subjects.
When measured objectively with SWAmini, group dif-
ferences were seen for all parameters except light PA
and were most pronounced for higher intensities, indi-
cating the generally lower participation of PwMS in
strenuous physical activities. The three most distinctive
parameters were step count, mean METs and active
METs. This supports the description of changes in PA as
(1) reduction in global walking mobility and (2) reduced
activity-related EE [7, 33, 34].
Effect sizes ranged from 0.63 to 0.86, which is compar-
able to previous reports of large MS cohorts [28, 35–37].
While daily step counts were similar to reports using
other devices [36, 38, 39], the mean duration of MVPA
activities observed in this study was higher than reported
from US cohorts (MVPA < 23.5 and < 33.8 min/day in
PwMS and HC) [35, 36] but lower than in other non-
diseased populations [40]. Besides different recruitment
bias and assessment devices, differences in activity life-
style may also contribute.
An exploratory analysis of parameter inter-correlations
(Additional file 2: Table S2) revealed that mean METs
were most tightly associated with MVPA, active METs
most strongly related to the amount of vigorous PA
while step count showed only moderate correlations to
both, mean METs and MVPA. Its lack of association
with active METs and vigorous PA indicates that loco-
motor activity is predominantly performed within the
low to moderate intensity segments.
This underlines that step count and EE capture com-
plementary aspects of PA: subjects with gait or balance
impairment may walk similar distances as HC but at
lower speed (lower intensity) or – conversely - walk less
efficiently, thus increasing the energy expended per step,
which has indeed been shown in PwMS [41, 42].
Although our cohort included rather physically active
PwMS, we observed a generally low amount of vigorous
activities in PwMS with only one subject performing
very vigorous PA, which impeded statistical comparison
for this parameter. Concerning light activities, our re-
sults imply that this activity segment represents inevit-
able ADL activities, performed to a similar extent by HC
and PwMS. It should further be noted that the group
differences in PA relate to a segment of only about
10 min per hour, while both groups spend the largest
part of their wake-time physically inactive. According to
Fig. 2 Selected activity parameters from IPAQ related to EDSS score.
a Walking duration, b MPA duration and c Total EE. Results of HCs
are depicted in yellow for reference, all PwMS results are depicted in
blue. Lines, boxes, whiskers as in Fig. 2. Please note that the one subject
with EDSS 1.5 was excluded in the data cleaning process according to
the IPAQ manual
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Fig. 3 IPAQ categories of physical activity level. a Frequency per category and group, b Relation with EDSS, c Relation with SWAmini Step count
and d Relation with SWAmini Mean METs. HCs are depicted in yellow, PwMS in blue. Please note that c and d include data from all subjects,
PwMS and HC
Table 3 Results of HAQUAMS total and susbcores reported as median (variance) and range in 26 PwMS and their association with
daily physical activity according to SWAmini parameters (Spearman correlations)
HAQUAMS
parameter
Median
(variance)
Min-Max SWAmini
Step count per hour Mean METs Active METs LPA MPA VPA
rho p rho p rho p rho p rho p rho P
Fatigue 2.61 (.866) 1.00–4.25 −.136 .509 −.369 .064 −.156 .446 .350 .080 −.244 .230 −.233 .253
Thinking 2.75 (.980) 1.00–4.50 −.061 .768 −.109 .595 −.186 .364 .124 .547 −.065 .754 −.187 .361
Mobility lower limb 2.13 (.672) 1.00–3.75 −.442 .024 −.222 .275 −.064 .755 −.069 .738 −.439 .025 −.310 .123
Mobility upper limb 1.30 (.300) 1.00–3.40 −.178 .385 −.004 .985 .054 .795 −.030 .884 −.267 .188 .000 .999
Communication 2.00 (.561) 1.17–3.83 −.114 .579 −.098 .633 −.083 .689 −.040 .845 −.053 .797 −.006 .975
Mood 2.50 (.716) 1.40–4.60 −.034 .868 −.067 .745 −.202 .322 .128 .533 −.313 .120 −.128 .533
Pain/Sensory 2.00 (.600) 1.00–3.50 .145 .480 −.083 .686 −.232 .255 −.066 .749 .206 .313 −.473 .015
Bowel/Bladder 1.67 (.549) 1.00–3.33 .000 .999 −.023 .913 .099 .631 −.134 .515 −.127 .538 .090 .662
Contentment 2.00 (.427) 1.00–4.00 −.060 .776 −.026 .903 −.372 .067 −.144 .492 −.161 .442 −.365 .073
Total 2.20 (.299) 1.20–3.39 −.227 .264 −.262 .196 −.212 .298 .130 .528 −.368 .065 −.257 .205
Pain/sensory and bowel/bladder were included in addition to published HAQUAMS subscores. Contentment refers to a single-item question. Significant results at level
of <0.05 are given in bold
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the MET definition of light PA, this may comprise low-
intensity locomotor activity as well as sedentary time
except sleeping which explains the seeming discrepancy
to reports of increased sedentary time in PwMS [43, 44].
The effect of occupational status on PA was somewhat
unexpected in its direction (tendency to even larger
weekend – weekday difference in unemployed subjects)
and small effect size, as others reported employment as
a relevant factor for PA among PwMS [5, 35, 44, 45],
however, in much larger cohorts. From our observation
of a lower proportion of PwMS employed (Table 1), that
even seems to decrease with higher EDSS scores (Add-
itional file 3: Figure S1), we conclude that effects of occupa-
tional status and MS progression on daily PA may be
difficult to distinguish or even counteract each other.
Group differences in PA could also be detected with the
subjective IPAQ long form and were observed for the
amount of MPA and MVPA, but not for the time spent
walking. Convergent to SWAmini data, PwMS perceive
themselves as (and according to SWAmini “are”) less
engaged in higher intensity physical activities at group level.
This is remarkable given the small group size and previous
reports on a tendency for unfit (otherwise healthy) individ-
uals to overestimate their participation in MVPA activities
by up to 37% [46]. The questionnaire was easily applicable
in our cohort and data exclusion or truncation rules had to
be applied at similar rates in HC and PwMS.
With respect to IPAQ walking, it has to be considered,
however, that IPAQ data refer only to reported bouts of
over 10 min, although most locomotor activity, i.e. steps
accumulated during the day, is likely to occur in shorter
bouts. When relating results from subjective to objective
assessment, we therefore subsumed reported walking
activity within moderate PA.
The observed convergence for this matched parameter
pair (r .507) was higher than expected from previous results
obtained with other means of objective and subjective PA
assessment in PwMS [36, 39, 47–49]. Similarly, the relation
of IPAQ PA levels to selected SWAmini PA parameters
roughly converge with commonly used cut-offs to detect
low and highly active lifestyles by step count or mean METs
(step count low level < 5000 steps/day, moderate level
5000–7500 steps/day and high level > 7500 steps/day; mean
METs: very low level < 1.2 METs, low level 1.2–1.4 METs,
moderate level 1.4–1.6 METs and high level > 1.7 METs)
[23, 38]. This supports the validity of this easily applicable
classification, e.g. for screening purposes. The trend seen
for group difference (p = 0.15) is likely due to small sample
size. Only one person with MS was classified as highly
active, probably due to high IPAQ Walking durations
despite a not specifically high step count around 7000/day
and mean METs of 1.5.
This part of analysis further suggested that step count ra-
ther differentiates high from moderate PA levels, which may
apply early in disease, while mean METs (related tightly to
MVPA) is more suited to distinguish between moderate and
low PA level. This further implies that increase in PA is me-
diated by different types of activity according to PA levels
and that different PA parameters may be suited to monitor
MS populations of different symptom severity.
Another aspect of IPAQ with relevance for intervention
design is the context of PA. From our data, it seems
unlikely that increases of PA in PwMS will be added as
leisure/sports activity, whereas supporting active
Table 4 Results of HAQUAMS total and susbcores reported as median (variance) and range in 26 PwMS and their association with
daily physical activity according to selected IPAQ
HAQUAMS
parameter
Median
(variance)
Min-Max IPAQ
Duration (min/day) EE (MET*min/day)
Walking MPA VPA Total Total
rho p rho p rho p rho p rho p
Fatigue 2.61 (.866) 1.00–4.25 .190 .364 −.340 .097 −.390 .054 −.053 .803 −.150 .475
Thinking 2.75 (.980) 1.00–4.50 .133 .527 −.227 .276 −.164 .433 −.055 .793 −.016 .939
Mobility lower limb 2.13 (.672) 1.00–3.75 −.107 .610 −.413 .040 −.441 .027 −.274 .185 −.221 .289
Mobility upper limb 1.30 (.300) 1.00–3.40 −.151 .471 −.210 .315 −.171 .413 −.326 .112 −.342 .095
Communication 2.00 (.561) 1.17–3.83 −.074 .725 −.201 .336 −.289 .160 −.180 .390 −.160 .444
Mood 2.50 (.716) 1.40–4.60 −.039 .855 .087 .678 −.073 .728 .044 .836 −.028 .895
Pain/Sensory 2.00 (.600) 1.00–3.50 .344 .092 .012 .955 .099 .639 .091 .664 −.016 .939
Bowel/Bladder 1.67 (.549) 1.00–3.33 .048 .818 .132 .528 .092 .663 .226 .227 .249 .229
Contentment 2.00 (.427) 1.00–4.00 −.253 .233 −.110 .610 −.221 .299 −.360 .084 −.489 .015
Total 2.20 (.299) 1.20–3.39 −.030 .887 −.219 .294 −.294 .154 −.143 .495 −.084 .690
Pain/sensory and bowel/bladder were included in addition to published HAQUAMS subscores. Contentment refers to a single-item question. Significant results at level
of <0.05 are given in bold
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transportation or integrate PA into subjects’ lifestyle [50,
51] seem more appropriate. In this respect, it is worth re-
considering and exploring the role of occupational status in
daily PA and, specifically, active transportation. With regard
to behavioral interventions, these probably need to be de-
signed and evaluated specific to cultural settings according
to activity lifestyle differences, for example between U.S.
and German populations.
SWAmini parameter correlations to EDSS were moderate
in magnitude, which is similar to previously reported coeffi-
cients between −.34 and −.70 [33, 39, 52–54]. Again,
inspection of the parameter plots per EDSS score (Fig. 2)
suggests reduced step count as an early feature in MS while
decline in the daily amount of MVPA occurs beyond
EDSS > 3, i.e. at stages with manifest decrease in walking
mobility.
Corresponding IPAQ – EDSS plots revealed, that despite
lower duration of MVPA in PwMS at group level, among
those less severely affected, self-report of moderate
activities was even higher than in HC. This paradoxical
relation was even more pronounced for subjectively
assessed walking duration and total EE. As discussed
above, this may be interpreted as either a larger perceived
exertion when physically active (despite unchanged or
lower activity counts on “objective” assessment) or a
systematic reporting bias in subjects aware of physical
limitations, which has been reported in different popula-
tions [13]. Despite this and with only a small number of
subjects remaining for IPAQ MPA and MVPA to EDSS
analysis, correlations with symptom severity were similar
to those observed with SWAmini. Further, IPAQ PA level
assignment was related to EDSS scores. Both support the
validity of IPAQ results in our PwMS cohort, although
interpretations from individual absolute IPAQ results
cannot be recommended.
With respect to HAQUAMS, we observed distributions
of subscores similar to those reported in another German
MS cohort [26] as well as expected correlations with
EDSS.
However, the amount of daily moderate PA or daily step
count were not related to HAQUAMS sum score, but
seemed only related to the perceived impact of MS on
lower limb function. This result was irrespective of the
means of PA assessment (Tables 3 and 4) and adds to previ-
ous findings that PA in PwMS is only indirectly related to
hrQoL, most likely mediated through physical function
[55], although data on this topic are not abundant. One
interventional study reported improved HAQUAMS total
scores with intervention along with improvements in lower
limb coordination [56]. Vice versa, decreased hrQoL as
such seems unrelated to decrease in PA but related to a
multitude of not directly disease-related factors [55, 57–61].
This implies, that interventions aiming to increase PA
should target walking ability and physical limitations of the
lower limbs, while the quantitative assessment of lower
limb function may be a potentially useful surrogate of PA
for intervention monitoring.
Our findings, in line with previous reports, support the
notion that both objective and subjective PA assessment
may be appropriate depending on the purpose and re-
sources of the study [39], a major limitation of both being
the inherent variability in PA that requires long-term
recording over several days. Further, specific limitations of
different devices - questionnaires or activity monitors -
have been studied in different populations [18, 42, 62, 63]
and rather point to an approximation of “true” PA from
different perspectives instead of one golden assessment
standard. Thus, individual PA parameters may rather be
interpreted as reflecting a subject’s activity level than as
meaningful quantitative parameters per se. Accordingly,
clinically meaningful differences as determined for step
count, for example, are expectedly large given the
generally high standard deviations within groups of
healthy subjects (here: 2397/day). It seems therefore
justified to evaluate the validity of more amenable and
standardized quantitative performance measures as
predictors of PA in PwMS. Our data add evidence to
previous findings that suggest measures related to
walking and lower limb function as most promising
candidates.
Conclusion
Both methods of assessment seem applicable in PwMS
and able to describe reductions in daily PA at group
level. Whether they can be used to track individual
effects of interventions to enhance PA levels needs
further exploration. The relation of PA measures with
hrQoL seen with lower limb mobility suggests lower
limb function not only as a major target for interven-
tion to increase PA but also as a possible surrogate for
PA changes.
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